MYGN

Myriad Genetics Inc. 10-Q Summary: Quarter Ended September 30, 2007

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Myriad Genetics, Inc., a biotechnology company focused on molecular diagnostics and drug development. The reporting period covers the three months ended September 30, 2007. The company operates three segments: research, molecular diagnostics, and drug development. As of October 30, 2007, there were 43,973,465 shares of common stock outstanding.

Key Financial Metrics

Margins: The molecular diagnostic gross profit margin was 84% for Q3 2007, compared to 74% in Q3 2006.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 44% year-over-year, driven primarily by a 49% increase in molecular diagnostic revenue. This growth is attributed to an expanded sales force, a direct-to-consumer marketing campaign, and increased market penetration in the Ob/Gyn sector.
• Expense Increases: Selling, general, and administrative (SG&A) expenses surged 87% to $26.5 million. This was due to increased sales commissions, headcount, marketing costs for the direct-to-consumer campaign, and bad debt expense ($1.4 million increase) resulting from higher sales volume.
• Profitability Improvement: Despite higher operating expenses, the net loss narrowed by 35% to $8.0 million, and the operating loss decreased by 23% to $11.6 million. This improvement was aided by a 10% decrease in molecular diagnostic cost of revenue due to operational efficiencies.
• Liquidity: Cash and cash equivalents decreased by $36.2 million during the quarter, primarily due to investing activities (net purchase of marketable securities and capital expenditures) and operating cash outflows, partially offset by $6.5 million in proceeds from stock option exercises.

Guidance, Outlook, and Risks

• Drug Development Pipeline: The company is advancing several drug candidates. Flurizan (tarenflurbil) for Alzheimer's disease is in two Phase 3 trials, with top-line results expected by the end of June 2008. Azixa for brain tumors is in Phase 2 trials. Vivecon for AIDS is in late-stage preclinical development, with an Investigational New Drug (IND) application planned for submission by December 2007.
• Future Losses: Management expects to incur losses for at least the next several years due to the costs of clinical trials, drug discovery, and the expansion of the molecular diagnostic business.
• Liquidity Outlook: The company believes existing capital resources are sufficient to fund operations for at least the next two years. However, future capital requirements depend on the progress of clinical trials and regulatory approvals.
• Risks: Key risks include the failure of clinical trials (specifically Flurizan and Azixa), delays in regulatory approval, the inability to commercialize new products, and the potential for sales of existing diagnostic products to decline or not grow at historical rates. There are no material legal proceedings currently pending.

Investor Verification Checklist

• Flurizan Trial Timeline: Verify the status and projected completion date of the U.S. Phase 3 trial for Flurizan, as results are critical for future drug revenue.
• Bad Debt Trends: Monitor the allowance for doubtful accounts and bad debt expense, which increased significantly ($1.4 million) alongside revenue growth.
• SG&A Sustainability: Assess whether the 87% increase in SG&A expenses is sustainable relative to revenue growth rates in future quarters.
• Cash Burn Rate: Review the net cash used in operating activities ($12.7 million) against the current cash balance ($107.2 million) to validate the "two-year runway" assertion.
• Share-Based Compensation: Note the $2.4 million expense for the quarter and the $36.1 million of unrecognized compensation cost remaining, which will impact future earnings.